Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD

Bone Marrow Transplantation

Volumn 46, Issue 12, 2011, Pages 1579-1580

  Jackson, K ^a   Curley, C ^a   Leach, J ^a   McLean, A ^a   Nakagaki, M ^a   Durrant, S ^a   Kennedy, G A ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ETANERCEPT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ASPERGILLOSIS; BACTERIAL INFECTION; CAUSE OF DEATH; CYSTITIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG FATALITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; INFECTION RATE; LETTER; LUNG HEMORRHAGE; LUNG TOXICITY; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SALVAGE THERAPY; SURVIVAL TIME; TREATMENT DURATION; VIRUS INFECTION;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84856081931     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.341     Document Type: Letter

References (8)

1. Martinez C, Solano C, Ferra C, Sampol A, Valcarcel D, Perez-Simon JA et al. Alemtuzumab as treatment of steroidrefractory acute graft-versus-host disease: results of a phase II study. Biol Bone Marrow Transplant 2009; 15: 639-642.
2. Schnitzler M, Hasskarl J, Egger M, Bertz H, Finke J. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Bone Marrow Transplant 2009; 15: 910-918.
3. Gomez-Almaguer D, Ruiz-Arguelles JG, Tarin-Arzaga LDC, Gonzalez-Llano O, Gutierrez-Aguirre H, Cantu-Rodriguez O et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Bone Marrow Transplant 2008; 14: 10-15. (Pubitemid 350286746)
4. Schub N, Gunther A, Schrauder A, Claviez A, Ehler C, Gramatzki M et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant 2011; 46: 143-147.
5. Kennedy GA, Butler J, Western R, Mrton J, Durrant S, Hill GR. Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/-mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 2006; 37: 1143-1147. (Pubitemid 43871525)
6. Carella AM, Beltrami G, Scalzulli AM, Carella Jr AM, Corsetti MT. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant 2004; 33: 131-132. (Pubitemid 38159720)
7. Wandroo F, Auguston B, Cook M, Craddock C, Mahendra P. Successful use of Campath-1H in the treatment of steroid refractory liver GVHD. Bone Marrow Transplant 2004; 34: 285-287. (Pubitemid 39136842)
8. Glucksberg H, Strob R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.